Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 861.80B +29.3% |
| Revenue (ttm) | 336.53B +6.1% |
| Net Income | 35.05B +0.5% |
| EPS | 60.34 +0.9% |
| Shares Out | 575.38M |
| PE Ratio | 24.82 |
| Forward PE | 19.51 |
| Dividend | 8.00 (0.53%) |
| Ex-Dividend Date | n/a |
| Volume | 2,506,467 |
| Open | 1,454.00 |
| Previous Close | 1,443.70 |
| Day's Range | 1,446.40 - 1,503.10 |
| 52-Week Range | 1,016.10 - 1,550.00 |
| Beta | 0.04 |
| Analysts | Buy |
| Price Target | 1,513.14 (+1.02%) |
| Earnings Date | Aug 7, 2026 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretrovira... [Read more]
Financial Performance
In fiscal year 2026, Aurobindo Pharma's revenue was 336.53 billion, an increase of 6.08% compared to the previous year's 317.24 billion. Earnings were 35.05 billion, an increase of 0.54%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for AUROPHARMA stock is "Buy." The 12-month stock price target is ₹1,513, which is an increase of 1.02% from the latest price.
News
Aurobindo Pharma's subsidiary faces five observations following US FDA inspection
Aurobindo Pharma Limited's stepdown subsidiary, Eugia Steriles Private Limited, recently underwent a pre-approval inspection by the United States Food and Drug Administration (US FDA). The inspection,...
Pharma sector stocks today, June 19: IPCA Labs up 2.54%, Aurobindo Pharma gains 0.93%, Orchid Pharma falls 1.97%
Pharma stocks traded largely in positive territory on June 19, 2026, during the early morning session, with most stocks posting modest gains even as the broader market fell sharply. The…
Aurobindo Pharma receives US FTC approval for Lannett acquisition
Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has received approval from the US Federal Trade Commission (FTC) for its acquisition of Lannett Comp...
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett
The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said...
Pharma sector stocks today, June 17: Aurobindo Pharma gains 2.26%, Panacea Biotech falls 1.80%, Cipla down 0.32%
Pharma stocks traded mixed on June 17, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Top losers today: gujarat state petronet at ₹268.35 down 7.13%, aurobindo pharma at ₹1,408.30 falls 4.38%, zee entertainment at ₹108.49 slips 3.65%
The Indian stock market showed a positive trend today with the SENSEX rising to 76,264.33, up by 0.97%, and the NIFTY 50 climbing to 23,853.90, marking a 0.98% increase. However,…
Stocks to watch on June 15: Aurobindo Pharma, Patanjali Foods, Cyient, Dr Reddy's, JSW Energy, Aditya Birla Capital and more
Indian equities head into Monday's session with a heavy mix of corporate actions, regulatory developments, fundraises and order wins across pharma, power, capital markets and infrastructure. Adding to...
Aurobindo Pharma's Eugia Unit-III receives OAI classification from US FDA
Aurobindo Pharma has announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., has received an 'official action indicated' (OAI) classification from the US Food and Drug Administrati...
Aurobindo Pharma shares jump over 2% after USFDA approval for Tofacitinib Tablets with US$ 494 million market size
Aurobindo Pharma shares surged more than 2% in early trade on Friday, June 5, after the company announced that it had received final approval from the US Food & Drug…
Top stocks for trade today, June 5: Aurobindo Pharma, Lupin, CG Power, ACME Solar, Ola Electric, Go Digit in focus
Several companies are likely to remain in focus on Friday, June 5, following significant corporate announcements, regulatory approvals, fundraising activities, facility expansions, and block deals. St...
Aurobindo Pharma receives US FDA approval for Tofacitinib Tablets with US$ 494 million market size
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg dosages. These tablets…
Top stocks for trade today, June 4: Aurobindo Pharma, NBCC, BHEL, Hero MotoCorp, Indian Energy Exchange, HFCL and more in focus
Indian stock market participants may keep an eye on several companies on June 4 following business updates, project announcements, operational developments and order wins disclosed by the respective f...
Aurobindo inaugurates TheraNym Biologics’ facility in Hyd
Aurobindo Pharma inaugurates TheraNym Biologics CRO/CMO near Hyderabad, investing ₹1,200 crore to boost biologics manufacturing, create 1,500 jobs; MSD anchor customer.
Aurobindo inaugurates biologics CRO TheraNym’s facility in Hyd
Aurobindo Pharma inaugurates TheraNym Biologics CRO/CMO near Hyderabad, investing ₹1,200 crore to boost biologics manufacturing, create 1,500 jobs; MSD anchor customer.
Aurobindo Pharma inaugurates TheraNym, a major biologics manufacturing facility
Aurobindo Pharma Limited has inaugurated TheraNym, a significant biologics contract manufacturing facility, marking a pivotal moment in India's pharmaceutical landscape. The facility, located in Borap...
Pharma sector stocks today, May 27: Panacea Biotech rises 2.83%, Wockhardt up 2.71%, Aurobindo Pharma down 0.17%
Pharmaceutical stocks traded mixed during the morning session on May 27, 2026. While some stocks posted decent gains, a few names saw mild selling pressure. The BSE Healthcare index rose…
Aurobindo Pharma's Eugia facility receives OAI classification from US FDA
Aurobindo Pharma has announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., has received an 'official action indicated' (OAI) classification from the US Food and Drug Administrati...
Aurobindo Pharma expands European footprint with new subsidiary in France
Aurobindo Pharma on Friday said its wholly owned step-down subsidiary, Agile Pharma BV, has incorporated a new wholly owned subsidiary in France named Arrow Pharma Production SAS, marking another step...
Pharma sector stocks today, May 22: Aurobindo Pharma falls 4.11%, Zydus Lifesciences rises 0.92%, Alembic Pharma up 1.06%
Pharmaceutical stocks traded mixed on May 22, 2026, during the morning session. While some stocks posted modest gains, a few names, including Aurobindo Pharma, witnessed sharp declines. The BSE Health...
Aurobindo Pharma Transcript: Q4 25/26
Record FY 2026 revenue and EBITDA margins were achieved, with strong growth across all segments and geographies. Outlook for FY 2027 is robust, targeting higher margins and double-digit growth in Europe, while biosimilars and CDMO strategies are set to drive long-term expansion.
Aurobindo Pharma Quarterly report: Q4 2026
Aurobindo Pharma has published its Q4 2026 quarterly earnings report on May 21, 2026.
Aurobindo Pharma Slides: Q4 2026
Aurobindo Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 21, 2026.
Top stocks for trade today, May 22: ITC, LIC, GAIL India, Max Healthcare, Paytm, Aurobindo Pharma and more
Indian stock markets are expected to track company earnings, block deal developments, and sector-specific triggers on May 22. Several companies, including ITC Limited, Life Insurance Corporation of In...
Aurobindo Pharma reports ₹8,853 crore revenue for Q4FY26 with 5.6% growth
Aurobindo Pharma Limited has announced its consolidated financial results for the fourth quarter and the fiscal year ending March 31, 2026. The company reported a 5.6% year-on-year increase in revenue...
Aurobindo Pharma Q4 Results: Shares jump over 2% ahead of earnings announcement
Shares of Aurobindo Pharma gained over 2% in intraday trade on Thursday ahead of the company’s Q4 FY26 results announcement, with investors closely tracking the stock ahead of its earnings…